Hubei Goto Biopharm Co.,Ltd.

300966

CNE100004K94

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 22/05/2024 am IST			5-day change	1st Jan Change
19.65 ^CNY	+2.29%		-4.61%	-14.45%

26/04	Hubei Goto Biopharm Co.,Ltd. Proposes Final Cash Dividend for 2023	CI
25/04	Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hubei Goto Biopharm Co.,Ltd. has filed an IPO.

January 04, 2021 at 10:30 am IST

Hubei Goto Biopharm Co.,Ltd. has filed an IPO. Security Name: A Shares Security Type: Common Stock Securities Offered: 29,000,000

Latest news about Hubei Goto Biopharm Co.,Ltd.

Hubei Goto Biopharm Co.,Ltd. Proposes Final Cash Dividend for 2023	27/04	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	09/04	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/23/24	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Hubei Goto Biopharm Issues $53 Million Convertible Bonds	24/22/24	MT
Hubei Goto Biopharm to Guarantee 46% of Unit’s Loan	25/22/25	MT
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Hubei Goto Biopharm Co.,Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022	25/22/25	CI
Hubei Goto Biopharm Co.,Ltd. Approves Cash Dividend for 2021	17/22/17	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Hubei Goto Biopharm Co.,Ltd. Proposes Cash Dividend for 2021	23/22/23	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
Certain A Shares of Hubei Goto Biopharm Co.,Ltd. are subject to a Lock-Up Agreement Ending on 9-APR-2022.	09/22/09	CI
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Hubei Goto Biopharm Co.,Ltd. Announces Executive Changes	19/21/19	CI
Hubei Goto Biopharm : to List 1.5 Million Shares Post IPO Lockup; Shares Jump 4%	13/21/13	MT
Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	25/21/25	CI
Hubei Goto Biopharm Co.,Ltd. has completed an IPO in the amount of CNY 238.96 million.	02/21/02	CI
Hubei Goto Biopharm Co.,Ltd. has filed an IPO.	04/21/04	CI
Yicheng Goto Pharmaceuticals Co., Ltd announced that it has received funding from Shenzhen Capital Group Co., Ltd..	31/15/31	CI

Chart Hubei Goto Biopharm Co.,Ltd.

Duration

Period

More charts

Hubei Goto Biopharm Co Ltd is a China-based company mainly engaged in the research and development, production and sales of steroidal drug raw materials. The Company's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The Company's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUBEI GOTO BIOPHARM CO.,LTD.	-14.45%	313M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+63.75%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+5.47%	8.82B